European HealthTech and MedTech M&A Predictions for 2026
- Nelson Advisors
- 43 minutes ago
- 8 min read
The European HealthTech and MedTech M&A landscape in 2026 is poised for significant strategic acceleration, marking a transition from cautious, volume-driven dealmaking to high-value, transformative transactions. Deal flow is consolidating toward fewer but substantially larger deals, with market participants prioritising scalable technologies with robust clinical validation and AI integration capabilities.
Market Outlook and Deal Activity Forecast
Global M&A volumes are expected to surge, with Goldman Sachs projecting deal flow could reach $3.9 Trillion in 2026, potentially surpassing the 2021 record. European healthcare M&A demonstrated remarkable resilience in 2025, with an 87% spike in deal value reaching €31.8 Billion in the first half of 2025, despite an 8% decline in deal count. This "bigger cheques, fewer bets" approach signals a maturing market where acquirers prioritise high-quality, high-value assets.
Investment bankers and dealmakers expect more transactional activity in healthcare in 2026 than was evident in 2025, with large listed healthcare businesses likely to prune their portfolios, creating carve-out opportunities for investors capable of such transactions. Half of European dealmakers surveyed expect M&A activity levels to increase over the next 12 months, despite considerable market volatility.
The European HealthTech market is valued at approximately $96.68 Billion in 2025 and projected to reach $222.22 Billion by 2030, representing an impressive 18.11% CAGR. The European medical technology market itself stands at roughly €170 billion in 2024, with Europe maintaining a positive medical devices trade balance of €5 Billion.
Strategic Drivers of M&A Activity
Artificial Intelligence as the Primary Catalyst
The single most potent catalyst driving deal value across both sectors is the urgent necessity to acquire advanced AI and Generative AI capabilities. AI captured 58% of Europe's total digital health funding in 2024, with investors demonstrating heightened enthusiasm for AI-enabled ventures due to their transformative potential in diagnostics, operations, and treatment personalisation.
Companies with proprietary AI algorithms, clinically validated solutions, and deep integration into existing healthcare workflows command premium valuations of 6x to 8x revenue, compared to the general HealthTech range of 4x to 6x revenue.
Key AI-driven M&A targets include:
· Ambient Clinical Intelligence and AI scribes for clinical workflow automation
· AI-powered diagnostics and medical imaging platforms
· Revenue Cycle Management platforms enhanced with automation
Pharma Patent Cliff Pressure
A major structural driver is the looming pharmaceutical patent cliff, with $180–400 Billion in branded drug sales at risk from patent expiries between 2026 and 2030. Major blockbuster drugs including Eliquis (2026), Keytruda, and Opdivo are losing exclusivity, forcing pharmaceutical giants to pursue aggressive M&A to fill pipeline gaps.
This has shifted dealmaking philosophy from "buying revenue" to "buying innovation," with preclinical and Phase I asset deals surging to account for over a quarter of total deal value in 2024, compared to just 8% for commercial-stage assets. Notable deals reflecting this trend include J&J's $14.6 Billion acquisition of Intra-Cellular, Merck's $10 Billion deal for Verona Pharma (a UK firm), and Sanofi's $9.5 Billion purchase of Blueprint Medicines.
Regulatory Environment as Competitive Filter
The convergence of high regulatory costs and technical complexity under MDR/IVDR, the AI Act, and EHDS is acting as a powerful competitive filter. High fixed compliance costs disproportionately strain under capitalised SMEs, accelerating strategic acquisitions by larger multinational incumbents like Medtronic and Philips that possess the internal compliance infrastructure to absorb these costs efficiently.
Key regulatory timelines for 2026:
· Full high-risk AI system requirements under the EU AI Act take effect August 2026
· AI systems intended as medical devices must complete conformity assessment by August 2026
· EHDS implementation phases continue, with Digital Health Authorities established by 2027
MedTech Europe has urged the European Commission to provide regulatory relief by early 2026, including targeted postponement of re-certification requirements to avoid bottlenecks.
Mega-Deal Predictions and Sector Focus Areas
Mega-Deals on the Rise
The year 2026 is projected to witness a substantial increase in mega-deals ($5 Billion and above), following momentum established in 2025. Strategic imperatives for incumbents are two fold: defensive acquisitions to counter macroeconomic and regulatory headwinds (including the impact of GLP-1 drugs on certain device markets) and offensive acquisitions to secure high-growth therapeutic areas including neuro vascular, advanced diagnostics and AI data platforms.
High-Priority Acquisition Targets
Sector | Focus Area | Key Buyers |
HealthTech: Provider Operations/RCM | AI-enabled revenue cycle management and billing automation | PE firms, health systems |
HealthTech: Clinical DTx/SaMD | Clinically validated digital therapeutics with clear reimbursement pathways | Pharma/Biotech, Large Payers |
MedTech: Surgical Robotics | Autonomous/AI-driven surgical platforms | MedTech incumbents |
MedTech: Diagnostics | AI-powered diagnostics and imaging platforms | Tech giants, pharma |
HealthTech: Telemedicine | Scalable digital care delivery platforms | Strategic buyers, PE |
Notable recent transactions establishing precedent include:
· Hims & Hers acquisition of Zava (UK-based) for European market expansion across UK, Germany, France, and Ireland, expected to be accretive by 2026
· Intuitive Surgical's acquisition of distribution businesses in Italy, Spain, Portugal, Malta, and San Marino, closing in 2026
· Zimmer Biomet's acquisition of Monogram Technologies for AI-driven orthopaedic robotics
· Teleflex's €760 million acquisition of Biotronik's vascular intervention unit
Private Equity's Expanding Role
Private equity engagement has been particularly strong, with sponsor buyout deals in European healthcare increasing by 276% to €29.6 Billion year-to-date 2025 compared to 2024. The volume of European healthcare PE deals reached a record high in 2025, surpassing the previous peak set in 2021.
Key PE strategies for 2026:
Buy-and-Build Consolidation: The most critical strategy for PE funds deploying capital into European HealthTech in 2026 is the Buy-and-Build model. The structural fragmentation within HealthTech and MedTech makes it an ideal environment for B&B strategies, allowing PE to create scale through platform acquisitions and technology integration.
AI-Native Mergers: PE firms are strategically merging legacy healthcare businesses with AI-native startups, exemplified by New Mountain Capital's plan to combine three companies into an AI-based revenue cycle management platform.
Club Deals: PE firms are partnering with corporate buyers to "double down" on specific therapeutic areas, sharing risk and leveraging deeper sector expertise.
Major PE fund closings include Sofinova Partners' €650 Million Capital XI fund, specifically targeted at early-stage HealthTech and MedTech companies—one of the largest early-stage healthcare funds in Europe recently.
Geographic Hotspots
Europe is expected to continue absorbing market share from regions like the Americas, which saw declines
in H1 2025. The UK led European digital health funding with $409 Million in Q3 2025, followed by Germany, France, and the Nordics.
United Kingdom: The UK market is strategically important and forecasted to register the highest CAGR in European Health IT. The NHS 10-Year Health Plan introduces standardised value-based procurement guidance for devices and digital products starting early 2026, with approximately £10 Billion annual MedTech spend now shifting from cost-driven to outcome-driven purchasing.
Nordic Countries: Continue to demonstrate strength in AI-driven oncology and preventive health, with deals like Helsinki-based Gosta Labs' €7.5 Million Seed round for clinical-grade AI.
Germany, France, and Netherlands: Remain consistent performers, though Germany and Italy experienced deal value declines in H1 2025.
European Health Data Space (EHDS) Impact
The EHDS, adopted in March 2025, represents the EU's most ambitious attempt to unlock health data potential while safeguarding fundamental rights. This regulation is expected to be transformative for M&A by creating new opportunities for data-driven acquisitions.
Implementation timeline:
· 2025–2027: Adoption of implementing acts defining technical standards and interoperability requirements
· By 2029: Primary use regulations enabling cross-border EHR access
· By 2031: Secondary use of health data fully operational for research and AI training
For M&A purposes, the EHDS creates acquisition opportunities around:
· Dynamic data consent solutions and data flow infrastructure
· Health data access body (HDAB) service providers
· AI platforms leveraging structured, cross-border health data
The EU has committed €14.4 million through the EU4Health-2026 call specifically for health data for biotech innovation leveraging the EHDS.
Five Megatrends Shaping 2026
Based on comprehensive analysis, five dominant megatrends are forecast to shape European HealthTech and MedTech in 2026:
Electric Medicine (Bioelectronic Medicine): Expansion of neurotechnology and bioelectronic devices beyond deep-brain stimulation to include sophisticated Brain-Computer Interfaces and non-invasive neuromodulation.
SleepTech Integration: Convergence of professional sleep medicine and consumer wearables, part of broader remote patient monitoring and personalised healthcare
Ambient Clinical Intelligence: Widespread adoption of AI scribes and ambient voice technologies in European clinical settings, tightly regulated by the EU AI Act
Defence MedTech and Supply Chain Resilience: Heightened focus on strategic preparedness and secure, local manufacturing following geopolitical challenges
Dynamic Data Consent Models: Implementation of granular, user-controlled consent models under EHDS, enabling data sharing for AI development while ensuring GDPR compliance
Valuation Multiples and Investment Trends
Current European HealthTech valuation multiples show a "cautious yet discernible rebound":
Category | EV/Revenue Multiple | EV/EBITDA Multiple |
General HealthTech | 4x–6x | 10x–14x |
AI-driven solutions | 6x–8x+ | Premium above range |
Data monetisation platforms | 5.5x–7x | Premium above range |
Value-based care solutions | 5.5x–7x | Premium above range |
Smaller/unprofitable startups | 3x–4x | N/A |
Key drivers of valuation premiums include proprietary AI algorithms, recurring revenue models, regulatory clarity and compliance, and integration with Electronic Health Records.
Strategic Recommendations
For Founders and Sellers:
· Prioritise AI integration and clinical validation to command premium valuations
· Ensure regulatory compliance with MDR/IVDR and prepare for AI Act obligations by August 2026
· Develop interoperability with EHR systems and EHDS standards (OMOP, FHIR)
For Strategic Acquirers:
· Focus H1 2026 on regulatory infrastructure plays ahead of EHDS implementation
· Target AI-native platforms that can be integrated across existing portfolios
· Consider bolt-on acquisitions in high-growth verticals: mental health tech, femtech and preventive care
For Private Equity:
· Deploy Buy-and-Build strategies leveraging market fragmentation
· Target Series B+ companies with proven unit economics for M&A-centric exits
· Form club deals with corporate buyers in attractive therapeutic areas
The fundamental market prediction for 2026 is that the alleviation of antitrust risk, coupled with significant capital availability, empowers CEOs to execute acquisitions that secure platform-level AI technology and address deep-seated portfolio vulnerabilities, marking a definitive shift toward complex, necessary transformation in European HealthTech and MedTech.
Nelson Advisors > MedTech and HealthTech M&A
Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Us @ HealthTech events
October 2025
Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel
Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel
NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland
Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel
November 2025
HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel
MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel
MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards
Leaders in Health Summit 2025
December 2025
HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel
Healthcare Club, IESE Business School, Barcelona, Spain
HealthInvestor Power List Awards 2025, London, UK – Judging Panel
